33
Views
0
CrossRef citations to date
0
Altmetric
Articles

The polymethoxylated flavone hexamethylquercetagetin suppresses NF-κB signaling and inhibits cell survival in cervical carcinoma

, , , &
Pages 1-7 | Received 18 May 2022, Accepted 12 Oct 2022, Published online: 13 Nov 2022
 

Abstract

Nuclear factor-κB (NF-κB) contributes to the development and progression of cervical carcinoma. To construct a xenograft model, Ca Ski cells were subcutaneously inoculated into BALB/c nude mice. The relative protein expression of NF-κB p65, p-p65, IκBα, and p-IκBα were detected in hexamethylquercetagetin (HTQC) treated cervical carcinoma cells with or without tumor necrosis factor (TNF)α stimulation, or representative tumors tissues in xenograft mice. HTQC could prohibit NF-κB-derived luciferase activity in Ca Ski and C-33 A cells and inhibit the relative NF-κB p-p65 and p-IκBα expression with or without TNFα stimulation. At the same time, HTQC inhibited in vitro cell survival in a concentration-dependent manner and suppressed the tumor volume and weight in xenograft models. In summary, HTQC functions as an NF-κB inhibitor to prohibit the survival and proliferation of cervical carcinoma, which can be considered as an NF-κB target remedy in future clinical practice.

Author contributions

Yanan Sun, Nan Li, Yuru Cai, Xingnan Zhao, and Hongyu Yang conceived and designed the experiments; Yanan Sun, Xingnan Zhao, and Hongyu Yang performed the experiments; Yanan Sun and Hongyu Yang analyzed and interpreted the data and contributed reagents, materials, analysis tools, or data; Hongyu Yang wrote the paper.

Disclosure statement

No potential conflict of interest was reported by the author(s).

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.